Remove 2016 Remove Initial Public Offering Remove Returns
article thumbnail

If You Invested $30,000 in CRISPR Therapeutics in 2016, This Is How Much You Would Have Today

The Motley Fool

But just how well has the stock done over the years, and would it have proven to be a good investment if you bought shares at its initial public offering? A 240% return in less than a decade Oct. 19, 2016 was officially CRISPR Therapeutics' first day of trading. Should you buy CRISPR Therapeutics stock today?

article thumbnail

Arm IPOs on Nvidia's Success and AI Hype. Here's Why I'm Not Touching It

The Motley Fool

It was taken private by Softbank in 2016 at $32 billion, and its last private mark was $64 billion. In this video, I will talk about Arm's initial public offering (IPO) and why I don't think you should buy it on the back of the AI and Nvidia hype. Stock prices used were from the trading day of Aug. 25, 2023. .*

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Where Will GoPro Stock Be in 5 Years?

The Motley Fool

With its shares down a stunning 96% since their initial public offering (IPO) in 2014, GoPro (NASDAQ: GPRO) has been a nightmare for early investors. While the company tried to leverage its action cameras to create banded partnerships and original content, these efforts were stymied by bloated budgets and low returns.

article thumbnail

This Stock Turned $10,000 Into $263,690 Since Its 2016 IPO. Here's Why It's Not Too Late to Buy.

The Motley Fool

One stock that has provided stellar returns for its shareholders since its 2016 initial public offering (IPO) is Kinsale Capital (NYSE: KNSL). Since its IPO, Kinsale has returned more than 50% annually, or enough to turn $10,000 into $263,690 during the past eight years.

article thumbnail

Prediction: CRISPR Therapeutics Stock Could Be a Millionaire-Maker

The Motley Fool

The company's progress has not delivered strong returns in the past half-decade -- CRISPR Therapeutics has underperformed the market in this period. CRSP Total Return Level data by YCharts. billion, and it's harder to produce such returns at these levels; it will only get even more challenging. It's already well on its way.

article thumbnail

The Trade Desk Just Made a Bold Move in Connected TV. Time to Buy?

The Motley Fool

The chart below shows the stock's performance since its 2016 initial public offering. The 10 stocks that made the cut could produce monster returns in the coming years. The Stock Advisor service has more than quadrupled the return of S&P 500 since 2002*. TTD data by YCharts.

article thumbnail

Why Shopify Stock Is Probably a Buy After Its Post-Earnings Pullback

The Motley Fool

Since selling that business, the company has returned to profitability, helping the stock to rise significantly. Nonetheless, the sales multiple may offer some hope to investors. See the 10 stocks *Stock Advisor returns as of February 12, 2024 Will Healy has positions in Shopify. The Motley Fool has a disclosure policy.